<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122868">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132572</url>
  </required_header>
  <id_info>
    <org_study_id>MAG-AGN-MED-BRE-003</org_study_id>
    <nct_id>NCT02132572</nct_id>
  </id_info>
  <brief_title>Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants</brief_title>
  <acronym>RANBI</acronym>
  <official_title>Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle® Breast Implants in Primary Augmentation (RANBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan Medical</source>
  <oversight_info>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: National Institute for Health Research</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of
      reoperations with Allergan Natrelle® Breast Implants in primary augmentation (RANBI)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Cumulative incidence (i.e., incidence proportion) of first reoperation following the use of a BIOCELL™ textured 410 cohesive device.</measure>
    <time_frame>3 to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Implantation</condition>
  <arm_group>
    <arm_group_label>Natrelle® 410</arm_group_label>
    <description>Subjects receiving primary breast augmentation with Natrelle® 410 cohesive BIOCELL™ textured device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NATRELLE® 410 Breast Implants</intervention_name>
    <description>Surgical implant</description>
    <arm_group_label>Natrelle® 410</arm_group_label>
    <other_name>Anatomical, silicone-filled breast implants (low height/projection or extra high projection)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that have undergone a primary breast augmentation for aesthetic reasons with a
        BIOCELL™ textured 410 cohesive implant
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary breast augmentation (either bilateral or unilateral) operated on by the
             investigating surgeon with an infra-mammary approach 410 cohesive BIOCELL™ textured
             device (Truform 2 &amp; 3 only) has been implanted

          -  Primary breast augmentation 3 to 10 years prior to data collection

          -  Submuscular/dual plane or subglandular implant placement

        Exclusion Criteria:

          -  Breast augmentation for Poland Syndrome or amastia

          -  Breast reconstruction following mastectomy

          -  Revision or secondary breast reconstruction

          -  Non 410 device at initial breast augmentation

          -  Women subsequently diagnosed with fibrocystic disease considered to be pre-malignant

          -  Procedures of the breast not related to the primary breast augmentation (e.g.
             excision of skin lesions)

          -  Axillary or peri-areolar approach

          -  Glandular mastopexy augmentation (skin excision only)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Allergan Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Medical</last_name>
    <email>devicetrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
